GEN: Seasoned Drugs Offer Therapeutic Gold Mine

May 23, 2013Media coverage

Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More

The Path of Least Resistance: Repositioned Drugs Surpass New Brands

October 24, 2012Media coverage

Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More


August 10, 2012Media coverage

Q&A with K. Kimberly McCleary President & CEO The CFIDS Association of America A 2011 article in The Scientist alerted Suzanne to companies applying informatics to drug repurposing. One of them, Biovista, applied to our 2011 funding opportunity and its proposal to identify non-obvious drug therapies for CFS scored well for scientific and strategic merit. … Read More

Research 1st: Repurposing Old Drugs for CFS

June 15, 2012Media coverage

Biovista and its VP for Drug Discovery, Dr. Spyros Deftereos, MD, are featured in an online article in relation to CFIDS Association’s Research Institute Without Walls (RIWW) … The process of drug repurposing, also called “drug repositioning,” can slash the time and cost to bring new therapies to the patients who need them most, says … Read More